2017 Fiscal Year Final Research Report
Development of the therapeutic biomarker in bipolar disorder using CNV and methylation of target genes of mood stabilizers
| Project/Area Number |
15K09810
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Kibi International University (2017)
Kochi University (2015-2016) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
淵上 学 広島大学, 医歯薬保健学研究科(医), 助教 (40403571)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | Bipolar disorder / GSK3beta / BDNF / Lithium / CNV / Biomarker |
|---|
| Outline of Final Research Achievements |
Although it is known that lithium (Li) is effective in the treatment of bipolar disorders (BDs), a certain patient with BDs poorly responds to Li. It is hypothesized that structural genomic variations in the GSK 3 beta or BDNF gene may change the therapeutic efficacy of Li. One type of structural genomic variations is a copy number variation (CNV). So, we examined the rates of CNVs in GSK 3 beta and BDNF gene based on the Databases of Genomic Variations (DGV) in patients with BDs by quantitative real-time PCR. The therapeutic response to Li was evaluated by Alda Scale.
In the BDNF gene, while 5 BD patients were found to have 3 copies of exon IV region within nsv95132, there was no healthy subject having an amplified exon IV region. There was no significant difference in Alda Scale A between BD patients with 3 copies and 2 copies.These findings suggest that CNV within exon IV of the BDNF gene may not be involved in the therapeutic response to Li in patients with BD.
|
| Free Research Field |
分子精神医学
|
